Author

Nabil Baba Hamed

Observed names: N. Baba Hamed, Nabil Hamed

Institution: Hôpital Paris Saint-Joseph

Observed institution: Hôpital Paris Saint-Joseph

ORCID: 0009-0000-2886-9048

Observed ORCID: 0009-0000-2886-9048

OpenAlex ID: A5038761404

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

2024 · Stefano Kim, Francois Ghiringhelli, et al. · The Lancet Oncology · 30

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase�II study

2019 · Benoist Chibaudel, Jean‑Baptiste Bachet, et al. · International Journal of Oncology · 14

PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)

2018 · M.P. Ducreux, R. Desgrippes, et al. · Annals of Oncology · 4

Efficacy and Toxicity of (Chemo)Radiation Therapy in HIV+ Patients with Squamous Cell Anal Cancer, a Subgroup Analysis of the National Multicenter Cohort FFCD-ANABASE

2024 · Cecile Evin, Laurent Quéro, et al. · International Journal of Radiation Oncology*Biology*Physics · 2

OC-0284: First results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer

2018 · V. Vendrely, C. Lemanski, et al. · Radiotherapy and Oncology · 2

116P Angiopietin-2 (Ang-2) as a potential biomarker for guiding prescription of bevacizumab (bev) or anti-EGFR in RAS/BRAF wild-type (wt) unresectable metastatic colorectal cancer (mCRC): An exploratory analysis of the STRATEGIC-1 GERCOR-PRODIGE phase III trial

2024 · C. Borg, L-M. Dourthe, et al. · Annals of Oncology · 1

Cancer de l’anus

2024 · N. Baba Hamed · Elsevier eBooks

2024 · Leila Abbès, Amine Antonin Alam, et al. · Elsevier eBooks

Efficacité et toxicité de la (chimio)radiothérapie chez les patients séropositifs pour le VIH atteints d’un carcinome épidermoïde du canal anal, analyse en sous-groupe de la cohorte multicentrique Anabase

2021 · C. Evin, L. Quéro, et al. · Cancer/Radiothérapie

Anal cancer prevention: coming soon on the screens?

2017 · Vincent de Parades, Nadia Fathallah, et al. · Hépato-Gastro & Oncologie Digestive

Performance of 18FDG-PET in the management of non-metastatic HIV+ anal squamous cell carcinoma (ASCC).

2017 · Nabil Baba Hamed, Gael Deplanque, et al. · Journal of Clinical Oncology

Impact of OPTIMOX-aflibercept as first-line therapy on time to health-related quality of life deterioration in patients with unresectable metastatic colorectal cancer: results of the GERCOR VELVET phase II single arm study.

2016 · Julie Henriques, Amelie Anota, et al. · Journal of Clinical Oncology

FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidine-aflibercept as first-line therapy in patients with metastatic colorectal cancer: A GERCOR single-arm phase II study (VELVET).

2015 · Benoist Chibaudel, Thierry Andre, et al. · Journal of Clinical Oncology

Works count: 13

Citation count: 53

H-index: 3

I10-index: 2